Johanna Eriksson, Ph.D.

Consultant

Bio

  • Joined Pharmetheus in 2021, actively working in client projects and serving as deputy Project Portfolio Team Leader
  • Expertise includes physiological based pharmacokinetic modeling (PBPK) of preclinical and clinical data, especially for respiratory delivered medicines
  • M.Sc. (2015) and Ph.D. (2021) in Pharmaceutical Sciences from Uppsala University, Sweden
LinkedInGoogle Scholar

Pharmetheus affiliated publications

Bioavailability of three novel oral, sustained-release pellets, relative to an immediate-release tablet containing 500 mg flucytosine: A randomized, open-label, crossover study in healthy volunteersPredicting disease effect on the pharmacokinetics (PK) of sustained and immediate release formulations by applying physiologically based pharmacokinetic (PBPK) modellingPhysiologically based pharmacokinetic (PBPK) modelling of cabotegravir (CAB) to support design of microarray patches (MAPs) for the treatment of HIV positive childrenA platform for mechanistic modelling of subcutaneous administration with the effect of immunogenicity within the Open Systems Pharmacology frameworkDevelopment of a Physiologically-Based Pharmacokinetic Model for Coproporphyrin I (CP-I) Using the Open Systems Pharmacology Software Suite (PK-Sim and MoBi) for assessment of OATP1B-based DDIsPhysiologically based pharmacokinetic (PBPK) modeling of the oral absorption of 5-flucytosine to support further development of a sustained-release formulation for the treatment of cryptococcal meningoencephalitis